Department of Urology, Ludwig-Maximilians-University, Klinikum Grosshadern, Munich, Germany; Martini-Clinic Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Department of Urology, Ludwig-Maximilians-University, Klinikum Grosshadern, Munich, Germany.
J Urol. 2015 Feb;193(2):484-90. doi: 10.1016/j.juro.2014.08.096. Epub 2014 Aug 30.
We analyzed the impact of salvage lymph node dissection on the prognosis in patients with biochemical recurrence and positive lymph nodes on positron emission tomography/computerized tomography after radical prostatectomy.
We retrospectively analyzed the records of 58 patients who underwent pelvic and/or retroperitoneal salvage lymph node dissection from June 2005 to February 2012. Biochemical response was defined as prostate specific antigen less than 0.2 ng/ml 40 days after salvage treatment. Biochemical recurrence in those with a biochemical response was defined as prostate specific antigen greater than 0.2 ng/ml and increasing. Kaplan-Meier curves were used to assess time to biochemical recurrence, clinical recurrence and cancer specific survival. Cox and binary logistic regressions were used to determine factors influencing clinical recurrence and biochemical response.
Median followup after salvage lymph node dissection was 39 months. A total of 13 patients (22.4%) achieved a biochemical response. Only 1 patient remained free of biochemical recurrence during followup. Clinical recurrence developed in 25 patients (48.1%) after salvage treatment. Six patients (10.3%) died of disease, including 4 with indeterminate extralymphatic findings on positron emission tomography/computerized tomography before salvage therapy. The 5-year cancer specific survival rate was 71.1%. Patients with a complete biochemical response showed a trend toward a longer time to clinical recurrence (p = 0.20). Biochemical response did not influence cancer specific survival.
Salvage lymph node dissection in patients with biochemical recurrence and positive lymph nodes on positron emission tomography/computerized tomography led to a biochemical response in a certain proportion. Most patients progressed to biochemical recurrence after salvage treatment but almost half showed no further clinical recurrence. Cancer specific mortality occurred predominantly in patients with prior suspicion of extralymphatic lesions. Salvage lymph node dissection may delay androgen deprivation therapy and clinical recurrence in select patients.
我们分析了挽救性淋巴结清扫术对根治性前列腺切除术后生化复发且正电子发射断层扫描/计算机断层扫描阳性淋巴结患者预后的影响。
我们回顾性分析了 2005 年 6 月至 2012 年 2 月期间 58 例接受盆腔和/或腹膜后挽救性淋巴结清扫术患者的记录。生化缓解定义为挽救治疗后 40 天前列腺特异性抗原(PSA)<0.2ng/ml。生化缓解患者的生化复发定义为 PSA>0.2ng/ml 且持续升高。采用 Kaplan-Meier 曲线评估生化复发、临床复发和癌症特异性生存时间。采用 Cox 和二项逻辑回归分析确定影响临床复发和生化缓解的因素。
挽救性淋巴结清扫术后中位随访时间为 39 个月。共有 13 例(22.4%)患者达到生化缓解。随访期间仅有 1 例患者无生化复发。挽救治疗后 25 例(48.1%)患者出现临床复发。6 例(10.3%)患者死于疾病,其中 4 例在挽救治疗前正电子发射断层扫描/计算机断层扫描检查有不确定的淋巴结外表现。5 年癌症特异性生存率为 71.1%。完全生化缓解患者的临床复发时间有延长趋势(p=0.20)。生化缓解不影响癌症特异性生存。
生化复发且正电子发射断层扫描/计算机断层扫描阳性淋巴结患者行挽救性淋巴结清扫术可使一定比例的患者获得生化缓解。大多数患者在挽救治疗后进展为生化复发,但近一半患者无进一步的临床复发。癌症特异性死亡率主要发生在有淋巴结外病变可疑的患者中。挽救性淋巴结清扫术可能会延迟选择患者的雄激素剥夺治疗和临床复发。